Biopharma Insmed's Q2 revenue up 19%, beats estimates

Insmed

07/08/2025 12:09

Overview

Insmed Q2 2025 revenue grows 19% yr/yr, beating analyst expectations

Company reiterates 2025 ARIKAYCE revenue guidance of $405 mln to $425 mln

Insmed reports Q2 net loss of $321.7 mln, EPS at $1.70

Result Drivers

ARIKAYCE SALES - 19% revenue growth driven by increased ARIKAYCE sales across all regions

R&D EXPENSES - Increased due to higher manufacturing and compensation costs

COMMERCIAL READINESS - SG&A expenses rose due to preparations for Brensocatib launch

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$107.40 mln
$103.80 mln (14 Analysts)
Q2 EPS
-$1.7
Q2 Net Income
-$321.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Insmed Inc is $112.00, about 0.7% above its August 6 closing price of $111.26

Press Release: ID:nPn4M3HCma

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)